Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
Bluebird Bio Receives Non-compliance Notice From Nasdaq
Cerebral Adrenoleukodystrophy Pipeline Insight 2024, Featuring Key Players Minoryx Therapeutics, POXEL, Orpheris and Bluebird Bio
Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments
Is Bluebird Bio Stock a Buy?
Better Buy: Bluebird Bio Vs. Novavax
Is This Beaten-Down Stock a Good Acquisition Target?
Bluebird Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
Bluebird Bio's Hold Rating: Balancing Commercial Progress With Financial Restatements and Investor Concerns
Peeling Back The Layers: Exploring Bluebird Bio Through Analyst Insights
During the last three months, 4 analysts shared their evaluations of bluebird bio (NASDAQ:BLUE), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent rating
RBC Capital Reiterates Sector Perform on Bluebird Bio, Maintains $6 Price Target
RBC Capital analyst Luca Issi reiterates bluebird bio with a Sector Perform and maintains $6 price target.
Bluebird Biotech Set to Outperform Pessimistic Expectations – Broker | NASDAQ:BLUE
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Equal-Weight on Bluebird Bio, Lowers Price Target to $3
Wells Fargo analyst Yanan Zhu maintains bluebird bio (NASDAQ:BLUE) with a Equal-Weight and lowers the price target from $4 to $3.
Bluebird Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 150% Wells Fargo $4 → $3 Maintains Equal-Weight 03/19/2024 40% Wedbush $3 → $1.68 Maintains Neu
Wedbush Adjusts Bluebird Bio's PT to $1.72 From $1.68, Maintains Neutral Rating
bluebird bio (BLUE) has an average rating of hold and price targets ranging from $1 to $8, according to analysts polled by Capital IQ. Price: 1.15, Change: -0.05, Percent Change: -4.17
No Data